sorafenib has been researched along with acetylcysteine in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (acetylcysteine) | Trials (acetylcysteine) | Recent Studies (post-2010) (acetylcysteine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 14,580 | 1,046 | 5,960 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, A; Chen, L; Chen, S; Dai, X; He, F; Huang, C; Jiang, Y; Li, S; Li, T; Lian, J; Sun, L; Xiang, L; Xiao, H; Yan, X; Yang, M; Zhang, Y | 1 |
1 review(s) available for sorafenib and acetylcysteine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for sorafenib and acetylcysteine
| Article | Year |
|---|---|
Dichloroacetate enhances the anti-tumor effect of sorafenib via modulating the ROS-JNK-Mcl-1 pathway in liver cancer cells.
Topics: Acetylcysteine; Animals; Anthracenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Dichloroacetic Acid; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Hepatocytes; Humans; Liver Neoplasms; Male; MAP Kinase Kinase 4; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |